Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy.

IF 0.9 4区医学 Q4 SURGERY

Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery Pub Date : 2026-04-06 Epub Date: 2026-02-25 DOI:10.4274/tjtcs.2025.28900

Ahmet Kayahan Tekneci, Hasan Yavuz, Gizem Keçeci Özgür, Tevfik İlker Akçam, Ayşe Gül Ergönül, Kutsal Turhan, Alpaslan Çakan, Ufuk Çağırıcı

{"title":"Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy.","authors":"Ahmet Kayahan Tekneci, Hasan Yavuz, Gizem Keçeci Özgür, Tevfik İlker Akçam, Ayşe Gül Ergönül, Kutsal Turhan, Alpaslan Çakan, Ufuk Çağırıcı","doi":"10.4274/tjtcs.2025.28900","DOIUrl":null,"url":null,"abstract":"Background: To investigate prognostic significance of systemic inflammation-related parameters in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma (MPM).Methods: Data from 55 patients were analyzed retrospectively. Demographic characteristics, survival outcomes and inflammation-related parameters (neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR], lymphocyte/monocyte ratio [LMR] and pan-immune inflammation value [PIV]) were evaluated.Results: Overall survival (OS) was 61.26±13.03 (3-79) months in patients with low NLR, whereas, it was 23.18±3.53 (1-147) months in patients with high NLR (p=0.012). No statistically significant differences in OS were detected according to LMR, PLR and PIV. In addition, OS was 24.40±4.91 (3-92) months in men and 52.8±10.92 (1-147) months in women (p=0.031).Conclusion: In this study, NLR was found to be associated with survival in agreement with the existing literature, thereby distinguishing it from other inflammatory markers as a prognostic factor. In clinical practice, predicting patient prognosis based on pre-treatment NLR may provide a valuable guidance for treatment decision-making.","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":" ","pages":"192-197"},"PeriodicalIF":0.9000,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051732/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjtcs.2025.28900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To investigate prognostic significance of systemic inflammation-related parameters in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma (MPM).

Methods: Data from 55 patients were analyzed retrospectively. Demographic characteristics, survival outcomes and inflammation-related parameters (neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR], lymphocyte/monocyte ratio [LMR] and pan-immune inflammation value [PIV]) were evaluated.

Results: Overall survival (OS) was 61.26±13.03 (3-79) months in patients with low NLR, whereas, it was 23.18±3.53 (1-147) months in patients with high NLR (p=0.012). No statistically significant differences in OS were detected according to LMR, PLR and PIV. In addition, OS was 24.40±4.91 (3-92) months in men and 52.8±10.92 (1-147) months in women (p=0.031).

Conclusion: In this study, NLR was found to be associated with survival in agreement with the existing literature, thereby distinguishing it from other inflammatory markers as a prognostic factor. In clinical practice, predicting patient prognosis based on pre-treatment NLR may provide a valuable guidance for treatment decision-making.

查看原文本刊更多论文

全身性炎症对行细胞减缩手术和胸内热化疗患者预后的影响。

背景：探讨系统性炎症相关参数对恶性胸膜间皮瘤（MPM）患者行细胞减缩手术和胸内高温化疗的预后意义。方法：回顾性分析55例患者的资料。评估人口统计学特征、生存结局和炎症相关参数（中性粒细胞/淋巴细胞比值[NLR]、血小板/淋巴细胞比值[PLR]、淋巴细胞/单核细胞比值[LMR]和泛免疫炎症值[PIV]）。结果：低NLR组总生存期（OS）为61.26±13.03（3-79）个月，高NLR组总生存期（OS）为23.18±3.53（1-147）个月（p=0.012）。LMR、PLR、PIV的OS差异无统计学意义。男性OS为24.40±4.91（3-92）个月，女性OS为52.8±10.92（1-147）个月（p=0.031）。结论：本研究发现NLR与生存相关，与现有文献一致，从而将其与其他炎症标志物区分开来，作为预后因素。在临床实践中，根据治疗前NLR预测患者预后可能为治疗决策提供有价值的指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery SURGERY-

CiteScore

1.00

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： The Turkish Journal of Thoracic and Cardiovascular Surgery is an international open access journal which publishes original articles on topics in generality of Cardiac, Thoracic, Arterial, Venous, Lymphatic Disorders and their managements. These encompass all relevant clinical, surgical and experimental studies, editorials, current and collective reviews, technical know-how papers, case reports, interesting images, How to Do It papers, correspondences, and commentaries.